Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ximelagatran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 17/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MASP2 | O00187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ximelagatran SCHEMBL19065093 | 1.00 | F2 (1.00) | F2PLATPRSS1F10ITGB3 | |
| Ximelagatran SCHEMBL15908919 | 1.00 | F2 (1.00) | F2PLATPRSS1F10ITGB3 | |
| Ximelagatran SCHEMBL14509860 | 1.00 | F2 (1.00) | F2PLATPRSS1F10ITGB3 | |
| Ximelagatran SCHEMBL7222774 | 0.94 | F2 (0.88) | F2PLATPRSS1F10ITGB3 | |
| SCHEMBL8081029 | 0.90 | F2 (0.81) | F2PLATPRSS1F10ITGB3 | |
| SCHEMBL8302614 | 0.88 | F2 (0.79) | F2PLATPRSS1F10MASP2 | |
| SCHEMBL8088279 | 0.88 | F2 (0.79) | F2PLATPRSS1F10ITGB3 | |
| SCHEMBL8083322 | 0.87 | F2 (0.78) | F2PLATPRSS1F10ALDH1A1 | |
| SCHEMBL6818264 | 0.87 | F2 (0.77) | F2PLATPRSS1F10ALDH1A1 | |
| SCHEMBL13777388 | 0.87 | F2 (0.76) | F2PLATPRSS1ALDH1A1MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7886 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| US-12584131-B2 | Methods of gene therapy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20260007597-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRUS-INDUCED AIRWAY FIBROSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2026-01-08 | — | — | US | claimed |
| WO-2025262269-A1 | MONITORING OF REVERSAL AGENTS FOR ANTICOAGULANTS | ENZYRE B.V. (NL) | 2025-12-26 | — | — | WO | claimed |
| EP-4658806-A1 | DISPOSABLE CARTRIDGE FOR CLASSIFICATION OF ANTICOAGULANT AND METHOD OF USE | Haemonetics Corporation (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250347706-A1 | DISPOSABLE CARTRIDGE FOR CLASSIFICATION OF ANTICOAGULANT AND METHOD OF USE | HAEMONETICS CORP (US) | 2025-11-13 | — | — | US | claimed |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| US-20250177502-A1 | THROMBIN AND FIBRINOGEN AS TARGETS FOR ATOPIC DERMATITIS DIAGNOSIS AND TREATMENT | CHILDRENS HOSPITAL MED CT (US) | 2025-06-05 | — | — | US | claimed |
| WO-2005030758-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES USEFUL AS HMG-COA REDUCTASE INHIBITORS AND METHOD OF PREPARATION THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050069527-A1 | Cell-based therapies for ischemia | CASE WESTERN RESERVE UNIVERSITY (US) | 2005-03-31 | — | — | US | claimed |
| WO-2005011645-A2 | SELECTED BETAINES AND THEIR USES | MESSADEK JALLAL (BE) | 2005-02-10 | — | — | WO | claimed |
| US-20050014770-A1 | Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-20040242536-A1 | controlled-release mixtures of plant extracts, gelation polymers and drugs such as ximelagatran, used for prophylaxis of cardiovascular disorders | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | claimed |
| WO-2004093881-A2 | USE OF DIPYRIDAMOLE OR MOPIDAMOLE FOR TREATMENT AND PREVENTION OF THROMBO-EMBOLIC DISEASES AND DISORDERS CAUSED BY EXCESSIVE FORMATION OF THROMBIN AND/OR BY ELEVATED EXPRESSION OF THROMBIN RECEPTORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-04 | — | — | WO | claimed |
| US-20040180812-A1 | Methods of treating and preventing proliferative disease | TECHNOLOGY CENTER | 2004-09-16 | — | — | US | claimed |
| CN-1518462-A | pharmaceutical preparation | — | 2004-08-04 | — | — | CN | claimed |
| EP-1401502-A1 | PHARMACEUTICAL FORMULATION | AstraZeneca AB (SE) | 2004-03-31 | — | — | EP | claimed |
| WO-2003000293-A1 | PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | claimed |